Growth Hormone Secretagogue Research Peptides
These compounds fall into two mechanistic families: GHRH analogs that act on the GHRH receptor, and ghrelin-receptor (GHS-R1a) agonists. Research interest lies in their differing selectivity profiles and effects on pulsatile secretion in animal models.
18
Certificates published
Published across 4 compoundsin this group, current and prior lots. Every certificate is issued by an independent laboratory and carries the issuing lab’s verification key, so each result can be checked with the laboratory directly.
Ipamorelin
5–10mg · COA published
Highly selective pentapeptide ghrelin receptor agonist, notable for minimal cross-activation of other pituitary axes.
- Purity
- 99.673%
- 4 lab certificates
CJC-1295 (no DAC)
5–10mg · COA published
Modified GRF (1-29) analog with four amino acid substitutions conferring resistance to enzymatic degradation.
- Purity
- 99.777%
- 5 lab certificates
Tesamorelin
10–15mg · COA published
Stabilized 44-amino-acid GHRH analog — the longest GHRH sequence in common research use.
- Purity
- 99.174%
- 6 lab certificates
IGF-1 LR3
1mg · COA published
83-amino-acid IGF-1 analog engineered for markedly reduced binding to IGF binding proteins.
- Purity
- 98.587%
- 3 lab certificates
Direct comparisons in this area
Shortlisting within a research area is where most of these decisions actually get made, so the pairs are compared on the same measured figures rather than on claims.
Ipamorelin vs CJC-1295 (no DAC)
Ghrelin receptor agonism versus GHRH receptor agonism — different receptors, frequently studied together for that reason.
CJC-1295 (no DAC) vs Tesamorelin
Truncated GHRH(1-29) against full-length GHRH(1-44). Sequence length is the whole distinction and it is routinely glossed over.
IGF-1 LR3 vs Tesamorelin
Direct IGF-1 receptor agonism versus upstream GHRH stimulation — acting at opposite ends of the same axis.
CJC-1295 (no DAC) vs IGF-1 LR3
IGF-1 LR3 vs Ipamorelin
Ipamorelin vs Tesamorelin
Certificates of analysis in this area
Other research areas